Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07117383 · ClinicalTrials.gov registry record · Phase 1
Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject
A Phase 1 study, sponsored by Aspargo Labs.
- Not yet
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07117383 is a Phase 1 study that has not yet begun recruiting, run by Aspargo Labs. The registered enrollment target is 72 participants.
The verdict
NCT07117383, a Phase 1 study, has not yet begun recruiting, sponsored by Aspargo Labs.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare how different sildenafil formulations are absorbed and tolerated in healthy adult males under fed conditions. The main questions it aims to answer are: Do Hezkue and Hezkue Turbo differ in absorption compared to other commercial sildenafil products? Are there any differences in safety or tolerability between the products? Researchers will compare multiple formulations to evaluate differences in drug absorption and side effects.
Interventions
- DEVICE ASP-001.1
- DRUG ASP-001
- DRUG Commercial Sildenafil and Sildenafil/Tadalafil Products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07117383
The ClinicalTrials.gov registry entry for NCT07117383 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aspargo Labs, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ASP-001.1 is the first listed.
NCT07117383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07117383 about?
NCT07117383 is a clinical study titled "Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject". The goal of this clinical trial is to compare how different sildenafil formulations are absorbed and tolerated in healthy adult males under fed conditions. The main questions it aims to answer are: Do Hezkue and Hezkue Turbo differ in absorption compared to other commercial sildenafil products? Ar...
What is the current status of trial NCT07117383?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-01. Estimated completion is 2026-03.
What interventions are being tested in trial NCT07117383?
The interventions under investigation include: ASP-001.1 (DEVICE), ASP-001 (DRUG), Commercial Sildenafil and Sildenafil/Tadalafil Products (DRUG).
Who is sponsoring clinical trial NCT07117383?
This trial is sponsored by Aspargo Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.